Methotrexate in Pediatric Osteosarcoma: Response and Toxicity in Relation to Genetic Polymorphisms and Dihydrofolate Reductase and Reduced Folate Carrier 1 Expression

Journal of Pediatrics

Volumn 154, Issue 5, 2009, Pages 688-693

  Patiño García, Ana ^a   Zalacaín, Marta ^a   Marrodán, Lucía ^a   San Julián, Mikel ^a   Sierrasesúmaga, Luis ^a  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DIHYDROFOLATE REDUCTASE; DOXORUBICIN; METHOTREXATE; REDUCED FOLATE CARRIER; REDUCED FOLATE CARRIER 1; UNCLASSIFIED DRUG; VINCRISTINE;

ALKALINE PHOSPHATASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; APLASIA; ARTICLE; BILIRUBIN BLOOD LEVEL; BLOOD; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FEASIBILITY STUDY; FEMALE; FOLATE METABOLISM; GENE; GENETIC POLYMORPHISM; GENOTYPE; HEMATURIA; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; METASTASIS; NEUTROPENIA; OSTEOSARCOMA; OSTEOSARCOMA CELL; PEDIATRICS; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; REAL TIME POLYMERASE CHAIN REACTION; SAMPLE; SCORING SYSTEM; SIDE EFFECT; TREATMENT RESPONSE; TUMOR BIOPSY; TUMOR NECROSIS; WORLD HEALTH ORGANIZATION;

ADOLESCENT; ANTIMETABOLITES, ANTINEOPLASTIC; BONE NEOPLASMS; CARRIER PROTEINS; CASE-CONTROL STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; FEMALE; FOLATE RECEPTORS, GPI-ANCHORED; FOLIC ACID; GASTROINTESTINAL DISEASES; GENOTYPE; HEMATOLOGIC DISEASES; HUMANS; KIDNEY DISEASES; MALE; METHOTREXATE; OSTEOSARCOMA; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; RECEPTORS, CELL SURFACE; RNA, MESSENGER; TETRAHYDROFOLATE DEHYDROGENASE;

EID: 64149090965     PISSN: 00223476     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpeds.2008.11.030     Document Type: Article

References (24)

1. RNTI. Registro Nacional de Tumores Infantiles. Instituto de Estudios Documentales e Históricos sobre la Ciencia (CSIC-Universitat de Valencia).
2. Link M.P., and Eilber F. Osteosarcoma. In: Pizzo P.A., and Poplack D.G. (Eds). Principles and Practice of Pediatric Oncology (1997), Lippincott-Raven, New York 889-976
3. Lewis I.J., Nooij M.A., Whelan J., Sydes M.R., Grimer R., Hogendoorn P.C., et al. Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst 99 (2007) 112-128
4. Robien K., Boynton A., and Ulrich C.M. Pharmacogenetics of folate-related drug targets in cancer treatment. Pharmacogenomics 6 (2005) 673-689
5. Sharp L., and Little J. Polymorphisms in genes involved in folate metabolism and colorectal neoplasia: A HuGE Review. Am J Epidemiol 159 (2004) 423-443
6. Weisberg I., Tran P., Christensen B., Sibani S., and Rozen R. A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab 64 (1998) 169-172
7. Kawakami K., Salonga D., Park J.M., Danenberg K.D., Uetake H., Brabender J., et al. Different lengths of a polymorphic repeat sequence in the thymidylate synthase gene affect translational efficiency but not its gene expression. Clin Cancer Res 7 (2001) 4096-4101
8. Mandola M.V., Stoehlmacher J., Zhang W., Groshen S., Yu M.C., Iqbal S., et al. A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels. Pharmacogenetics 14 (2004) 319-327
9. Dervieux T., Greenstein N., and Kremer J. Pharmacogenomic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritis. Arthritis Rheum 54 (2006) 3095-3103
10. Skibola C.F., Smith M.T., Hubbard A., Shane B., Roberts A.C., Law G.R., et al. Polymorphisms in the thymidylate synthase and serine hydroxymethyltransferase genes and risk of adult acute lymphocytic leukemia. Blood 99 (2002) 3786-3791
11. Serra M., Reverter-Branchat G., Maurici D., Benini S., Shen J.N., Chano T., et al. Analysis of dihydrofolate reductase and reduced folate carrier gene status in relation to methotrexate resistance in osteosarcoma cells. Ann Oncol 15 (2004) 151-160
12. Sowers R., Toguchida J., Qin J., Meyers P.A., Healey J.H., Huvos A., et al. mRNA expression levels of E2F transcription factors correlate with dihydrofolate reductase, reduced folate carrier, and thymidylate synthase mRNA expression in osteosarcoma. Mol Cancer Ther 2 (2003) 535-541
13. Guo W., Healey J.H., Meyers P.A., Ladanyi M., Huvos A.G., Bertino J.R., et al. Mechanisms of methotrexate resistance in osteosarcoma. Clin Cancer Res 5 (1999) 621-627
14. Drozdzik M., Rudas T., Pawlik A., Gornik W., Kurzawski M., and Herczynska M. Reduced folate carrier-1 80G>A polymorphism affects methotrexate treatment outcome in rheumatoid arthritis. Pharmacogenomics J 7 (2007) 404-407
15. World Health Organization. Handbook for reporting results of cancer treatment (1979), World Health Organization, Geneva, Switzerland Geneva, Switzerland
16. Barroso I., Luan J., Middelberg R.P., Harding A.H., Franks P.W., Jakes R.W., et al. Candidate gene association study in Type 2 Diabetes indicates a role for genes involved in b-cell function as well as insulin action. Plos Biology 1 (2003) 41-45
17. Shi Y.Y., and He L. Shesis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res 15 (2005) 97-98
18. Toffoli G., Russo A., Innocenti F., Corona G., Tumolo S., Sartor F., et al. Effect of methylenetetrahydrofolate reductase 677C->T polymorphism on toxicity and homocysteine plasma level after chronic methotrexate treatment of ovarian cancer patients. Int J Cancer 103 (2003) 294-299
19. Berkun Y., Abou Atta I., Rubinow A., Orbach H., Levartovsky D., Aamar S., et al. 2756GG genotype of methionine synthase reductase gene is more prevalent in rheumatoid arthritis patients treated with methotrexate and is associated with methotrexate-induced nodulosis. J Rheumatol 34 (2007) 1664-1669
20. Wessels J.A., Kooloos W.M., De Jonge R., De Vries-Bouwstra J.K., Allaart C.F., Linssen A., et al. Relationship between genetic variants in the adenosine pathway and outcome of methotrexate treatment in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 54 (2006) 2830-2839
21. Assaraf Y.G. Molecular basis of antifolate resistance. Cancer Metastasis Rev 26 (2007) 153-181
22. Ifergan I., Meller I., Issakov J., and Assaraf Y.G. Reduced folate carrier protein expression in osteosarcoma: implications for the prediction of tumor chemosensitivity. Cancer 98 (2003) 1958-1966
23. Mintz M.B., Sowers R., Brown K.M., Hilmer S.C., Mazza B., Huvos A.G., et al. An expression signature classifies chemotherapy-resistant pediatric osteosarcoma. Cancer Res 65 (2005) 1748-1754
24. Ochi K., Daigo Y., Katagiri T., Nagayama S., Tsunoda T., Myoui A., et al. Prediction of response to neoadjuvant chemotherapy for osteosarcoma by gene-expression profiles. Int J Oncol 24 (2004) 647-655